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Abstract
Introduction: Metastasis of ovarian serous carcinoma to breast and/or axillary lymph nodes represents an 
unusual event. Nevertheless, their detection and distinction from mammary carcinoma are of huge clinical importance 
because the treatment and prognosis diverge significantly. 
Case presentation: We report a case of a 47 year-old Caucasian female patient with unforeseen metastasis to 
the breast and to axillary lymph nodes due to ovarian serous carcinoma. 
Conclusion: In patients with history of OSC who present with axillary or breast mass, an accurate histological 
diagnosis should be obtained since this has a great impact on treatment outcomes.
oncoprotein. Immunohistochemical staining performed on the nodes 
was positive for WT-1, p16, and CA-125 while cytokeratin 20 (CK20) 
and gross cystic disease fluid protein-15 (GCDFP-15) were negative. 
According to microscopic and immunocytochemical findings, the 
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Introduction 
Ovarian serous carcinoma (OSC) usually compares at an advanced 
stage, but with disease limited to the peritoneal cavity in the majority 
of patients (roughly 85%) [1]. However, metastasis of ovarian cancer 
to retroperitoneal organs such as kidney or distant organ metastases 
involving  brain have also been previously stated but very few reports 
describe extra-abdominal lymph node involvement in this kind of 
tumour. In particular, metastases to breast from OSC are almost 
exceptional. Clinical studies have revealed that the incidence of 
metastases to breast arrays from 0.5-1.2% [2,3]. We present a case of 
metastatic carcinoma to breast in a patient with a known history of 
OSC and a new breast lump. Importantly, this case had histopathologic 
features that can be confused with ductal carcinoma in situ. 
Case Report
A 47-year-old Caucasian female patient with past medical history 
of stage IIA high grade serous OC 9 months after cytoreductive surgery 
and three lines of adjuvant chemotherapy (carboplatin AUC6 plus 
taxol 175 mg/mq every three weeks for 6 cycles) referred to the clinic 
for regular follow-up visit. CA-125 levels were normal and she had 
no evidence of disease. She had a very good primary response to OSC 
standard treatment. Her medical history was negative excluding OSC. 
On physical examination, a 2 cm diameter, non-tender, round, firm, 
and fixed breast mass was discovered in superior inner quadrant of the 
left breast of the patient. Patient was unaware of this mass. Left axilla 
examination was positive for two solid, fixed and nodes. 
On mammography, a mass of 18 mm was detected (Figure 1a). 
Sonogram of bilateral breasts was performed which showed a 29 × 21 
× 18 mm vascularized left breast mass (Figure 1b) and two suspicious 
left axillary lymph nodes of 12 and 15 mm respectively (Figure 1c). 
Whole body CT scan executed two months before was negative for 
other possible metatstatic sites. A surgical excision of the mass and 
an elective axillary clearance were made after accurate counselling 
and discussion of the treatment possibilities with the patient. No 
minor or major complications were collected. To a first microscopical 
examination, the breast mass was identified as a ductal carcinoma in 
situ. Thirteen lymph-nodes were gained from the axillary fat. Of the 
13 axillary lymph nodes got, five showed metastatic deposits that 
were identical to the ovarian primary. Immunohistochemical studies 
revealed that the tumour cells expressed estrogen receptor (80%) and 
progesterone receptor (20%). There was no expression of HER-2/neu 
 
Figure 1: A) Mediolateral oblique (MLO) view of a mammogram shows 
breast mass (red row). B) Breast mass with smooth margin and homogenous 
echotexture. Color Doppler reveals irregularly branching neovascularity. C) 
Round hypoechoic lymph node with a diffusely enlarged cortex is seen on US, 
and color Doppler US shows increased central flow.
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with axillary or breast mass, every effort should be made to obtain an 
accurate histological diagnosis since this has a great impact on treatment 
outcomes. It is critical to distinguish histologic pattern and recognize 
it from de novo ductal carcinoma in situ. Immunohistochemistry is 
crucial to confirm the diagnosis
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The breast and/or ipsilateral lymph node metastases were 
discovered at an average of 30 months after presentation as in our case 
(36 months). 
When tumours in the breast or axillary lymph nodes are discovered 
before or simultaneously with an OSC, diagnostic difficulties may 
arise. The use of immunohistochemical markers such as WT-1 and 
GCDFP-15 may aid in defining the origin of the tumour if an ovarian 
primary should be contemplated carefully, because the treatments of 
these two entities are completely different. 
Furthermore, metastatic cancer to the breast from an OSC is 
associated with a poor prognosis, infact the majority of patients dying 
in one year [6,7]. Kayikcioglu et al. [8] described the case of a patient 
that was initially stage IIC epithelial ovarian cancer. After two years, 
she presented with bilateral metastatic breast disease originated from 
the primary ovarian cancer. Although she was heavily treated, she died 
18 months after diagnosis. Breast metastases from ovarian cancer were 
found an average of 2 years after initial diagnosis [9] and were usually a 
clue of advanced disease. It is interesting that in our patients there was 
no evidence of disseminated disease at the beginning. 
Immunohistochemical markers may benefit in determining the 
origin of breast or axillary lymph node metastases. Yamamoto et al. 
[10] analysed WT-1 immunoreactivity in 119 patients with OSC and 
disclosed that WT-1 positivity is positively linked with high grade, 
advanced stage and higher Ki-67 index, higher bcl-2 expression and 
poorer outcome in a study. Although WT-1 positivity can be seen in 
many solid tumours, it has been recognized as a possible marker mostly 
for ovarian cancer. 
Conclusion
We suggest that, in patients with history of OSC who present 
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